Doctor's Notes

Online Eczema Care Versus Office Visits: What a 300-Patient Trial Found

AI-generated illustration: Dr. Arsy #003 office commute

Dr. Arsy Editorial Team · November 9, 2026

Teledermatology can reduce travel and scheduling barriers, but convenience matters only if clinical outcomes remain acceptable. A randomized trial assigned 300 adults and children with atopic dermatitis to an online team-based connected-health model or in-person care.[2]

What “equivalent” meant

The researchers defined equivalence margins before analyzing results. Differences in mean change were −0.01 for EASI, 0.38 for POEM and 0.06 for vIGA; all fell inside those margins. This supports equivalent average improvement for the tested model—not proof that every virtual service is interchangeable with every clinic.[2]

The care model is the intervention

Teledermatology quality depends on structured history, usable photographs, clinician access, follow-up and a clear escalation path. A rushed message exchange without those features is not the intervention studied. Prior trials and reviews have tested several online designs with varying populations, durations and outcomes.[6][7][8][9][10][11]

When an office examination may still be needed

Possible infection, rapidly worsening painful skin, eye involvement, diagnostic uncertainty, extensive disease, or a need for procedures may require in-person assessment. Image quality and skin tone can affect what is visible. Families of infants should not rely on photographs alone when a baby is unwell.

Preparing for a useful virtual visit

  • Photograph the rash in natural light from overview and close-up distances.
  • List all prescription and nonprescription products with strengths.
  • Record itch, sleep disruption and recent changes.
  • Ask how quickly the care team responds to deterioration.
  • Confirm where laboratory monitoring or an in-person examination will occur.

This trial supports a specific connected-care system as an evidence-based option. Choice of format should still reflect severity, access, patient preference and clinician judgment.[2][7][14][17]

Moisturizer context

Dr. Arsy Moisturizer #003 supports cosmetic hydration for dry, sensitive and eczema-prone skin. It was not tested in the study above and does not reproduce the effects of prescription treatment, phototherapy or a care-delivery program.

Related research

Research and clinical references

  1. Narrowband versus broadband UVB randomized trial.
  2. Online versus in-person atopic dermatitis care randomized trial.
  3. ROAD study of long-term topical therapy in pediatric eczema.
  4. TRuE-AD3 52-week ruxolitinib cream study in children.
  5. Western Japan Atopic Dermatitis Registry design.
  6. Teledermatology in atopic dermatitis systematic review.
  7. Telemedicine in atopic dermatitis meta-analysis.
  8. Teledermatology versus in-person follow-up randomized trial.
  9. Web-based consultations for parents of children with eczema.
  10. Direct-access online care randomized clinical trial.
  11. Direct-access online care and quality of life trial.
  12. Phototherapy for atopic eczema: Cochrane review.
  13. AAD adult systemic therapy and phototherapy guideline.
  14. AAD pediatric atopic dermatitis management guideline.
  15. AAD adult topical therapy guideline.
  16. AAP skin-directed management clinical report.
  17. AAAAI/ACAAI atopic dermatitis guideline.
  18. Ruxolitinib cream TRuE-AD1 and TRuE-AD2 phase 3 trials.
  19. Pediatric ruxolitinib cream maximum-use trial.
  20. Long-term proactive topical corticosteroid strategy trial.
  21. Twice-weekly fluticasone maintenance in atopic dermatitis.
  22. Topical corticosteroids for atopic eczema: Cochrane review.
  23. Educational and psychological interventions for eczema: Cochrane review.
  24. Atopic dermatitis outcome measurement harmonization.

Educational information only; not medical advice. Cited researchers and organizations do not endorse Dr. Arsy products.

← Back to Doctor's Notes